Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know

Core Viewpoint - Harmony Biosciences Holdings, Inc. (HRMY) has seen a 13.5% increase in share price over the past four weeks, closing at $39.54, with a potential upside of 29% based on Wall Street analysts' mean price target of $51 [1][12] Price Targets - The average of 10 short-term price targets ranges from a low of $28 to a high of $75, with a standard deviation of $13.58, indicating variability in analysts' estimates [2] - The lowest estimate suggests a decline of 29.2%, while the highest indicates an upside of 89.7% [2] Analyst Sentiment - There is strong agreement among analysts regarding HRMY's ability to report better earnings than previously predicted, which supports the view of potential upside [4][9] - The Zacks Consensus Estimate for the current year has increased by 6.8% over the past month, with no negative revisions [10] Zacks Rank - HRMY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [11] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the extent of HRMY's potential gains, it does provide a directional guide for price movement [12]